Literature DB >> 30191026

The clinical role of 'liquid biopsy' in hepatocellular carcinoma.

Jessica A Howell1,2,3,1,2,3, Rohini Sharma4,4.   

Abstract

Circulating free tumor DNA (ctDNA) is DNA released from necrotic or apoptotic tumor cells into the bloodstream. Absolute levels of ctDNA, as well as genetic mutations and epigenetic changes detected in ctDNA are useful biomarkers of tumor biology, progression and response to therapy in many tumor types and recent evidence suggests they may be useful in hepatocellular carcinoma (HCC). ctDNA detected in blood, therefore, offers a minimally invasive, easily repeated 'liquid biopsy' of cancer, providing real-time dynamic analysis of tumor behavior and treatment response that could revolutionize both clinical and research practice in HCC. In this review, we provide a critical summary of the evidence for the utility of ctDNA as a diagnostic and prognostic biomarker in HCC.

Entities:  

Year:  2015        PMID： 30191026      PMCID： PMC6095325          DOI： 10.2217/hep.15.38

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


  74 in total

1.  Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma.

Authors:  Gengming Huang; Joseph D Krocker; Jason L Kirk; Shehzad N Merwat; Hyunsu Ju; Roger D Soloway; Lucas R Wieck; Albert Li; Anthony O Okorodudu; John R Petersen; Nihal E Abdulla; Andrea Duchini; Luca Cicalese; Cristiana Rastellini; Peter C Hu; Jianli Dong
Journal:  Clin Chem Lab Med       Date:  2014-06       Impact factor: 3.694

2.  Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma.

Authors:  Michihisa Iida; Norio Iizuka; Isao Sakaida; Toyoki Moribe; Nozomi Fujita; Toshiaki Miura; Shigeru Tamatsukuri; Hideo Ishitsuka; Koichi Uchida; Shuji Terai; Yoshihiro Tokuhisa; Kazuhiko Sakamoto; Takao Tamesa; Takanobu Miyamoto; Yoshihiko Hamamoto; Masaaki Oka
Journal:  Oncol Rep       Date:  2008-10       Impact factor: 3.906

3.  Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.

Authors:  Ken Chen; Hong Zhang; Li-Na Zhang; Shao-Qing Ju; Jing Qi; Dong-Feng Huang; Feng Li; Qun Wei; Jing Zhang
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

4.  Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.

Authors:  Mengjun Wang; Ronald E Long; Mary Ann Comunale; Omer Junaidi; Jorge Marrero; Adrian M Di Bisceglie; Timothy M Block; Anand S Mehta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

5.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

6.  Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients.

Authors:  Priyanka Iyer; Abdel-Rahman Zekri; Chu-Wei Hung; Emily Schiefelbein; Kadry Ismail; Ahmed Hablas; Ibrahim A Seifeldin; Amr S Soliman
Journal:  Exp Mol Pathol       Date:  2009-10-07       Impact factor: 3.362

7.  Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.

Authors:  Gihan Hosny; Nahla Farahat; Hanan Tayel; Pierre Hainaut
Journal:  Cancer Lett       Date:  2008-03-03       Impact factor: 8.679

8.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

9.  Circulating tumor cells measurements in hepatocellular carcinoma.

Authors:  Franck Chiappini
Journal:  Int J Hepatol       Date:  2012-05-28

10.  Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma.

Authors:  Y Tokuhisa; N Iizuka; I Sakaida; T Moribe; N Fujita; T Miura; S Tamatsukuri; H Ishitsuka; K Uchida; S Terai; K Sakamoto; T Tamesa; M Oka
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640
View more
  2 in total

Review 1.  Systemic treatments for hepatocellular carcinoma: challenges and future perspectives.

Authors:  Francesco Tovoli; Giulia Negrini; Francesca Benevento; Chiara Faggiano; Elisabetta Goio; Alessandro Granito
Journal:  Hepat Oncol       Date:  2018-02-08

2.  MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma.

Authors:  Soon Sun Kim; Jung Woo Eun; Ji-Hye Choi; Hyun Goo Woo; Hyo Jung Cho; Hye Ri Ahn; Chul Won Suh; Geum Ok Baek; Sung Won Cho; Jae Youn Cheong
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.